CJC-1295 without DAC (Mod GRF 1-29)
NeuroprotectionNeurology research on CJC-1295 without DAC (Mod GRF 1-29) examines whether this short-acting ghrh analogue produces measurable CNS effects beyond peripheral activity. The cognitive case rests on three convergent threads: same ghrh-receptor agonism as dac variant four amino acid substitutions resist enzymatic cleavage. without the albumin-binding tail, the molecule clears in roughly half an hour — useful for evening dosing that mimics natural sleep-time gh pulse.; downstream consequences for monoamine and neurotrophic signalling; and reduction of chronic neuroinflammation. CJC-1295 without DAC (Mod GRF 1-29) is dosed at 100 mcg 1-3x daily subq via subq in cognitive-focused protocols, with the ~30 min pharmacokinetic profile shaping receptor occupancy timing.
Key Takeaways
Cognitive lens: CJC-1295 without DAC (Mod GRF 1-29) acts as a restorative compound rather than a stimulant for cognitive endpoints. CNS access pattern: BBB transport plus vagal-afferent gut-brain signalling and cerebral vascular effects. Mechanism: Same GHRH-receptor agonism as DAC variant. Neuro dose: 100 mcg 1-3x daily subq via subq; cognitive effects accumulate across 4-8 weeks. Cognitive stack partners: Semax, Selank, Semax + Selank Blend.
Same GHRH-receptor agonism as DAC variant. Four amino acid substitutions resist enzymatic cleavage. Without the albumin-binding tail, the molecule clears in roughly half an hour — useful for evening dosing that mimics natural sleep-time GH pulse. For cognitive endpoints specifically, this mechanism translates into restorative rather than stimulant effects: reduction of neuroinflammation, support for BDNF and NGF signalling, modulation of monoamine systems, and stabilisation of cerebral perfusion. The three subsections below examine CJC-1295 without DAC (Mod GRF 1-29)'s CNS access route, the neurotrophic and inflammatory effects, and the receptor-level pharmacology.
Monoamine and neurotrophic effects
CJC-1295 without DAC (Mod GRF 1-29)'s downstream effects on monoamine systems (dopamine, serotonin, occasionally noradrenaline) and on neurotrophic signalling (BDNF, NGF, NT-3) form the molecular substrate of its observed cognitive phenotype. Same GHRH-receptor agonism as DAC variant. Four amino acid substitutions resist enzymatic cleavage. Without the albumin-binding tail, the molecule clears in roughly half an hour — useful for evening dosing that mimics natural sleep-time GH pulse. For users tracking cognitive endpoints over the typical 1-3x daily subq dosing pattern at 100 mcg, the changes accumulate across 4–8 weeks rather than emerging acutely. The relevant clinical endpoints are sleep quality, recovery capacity, mood stability, and resilience to cognitive stressors.
Receptor pharmacology and selectivity profile
CJC-1295 without DAC (Mod GRF 1-29)'s receptor-level pharmacology determines its selectivity profile and its overlap with companion peptides. Same GHRH-receptor agonism as DAC variant. Four amino acid substitutions resist enzymatic cleavage. Without the albumin-binding tail, the molecule clears in roughly half an hour — useful for evening dosing that mimics natural sleep-time GH pulse. The selectivity (or lack thereof) for the principal target relative to off-target receptors is the basis for both the clinical phenotype and the side-effect profile. In stack design this matters: pairing CJC-1295 without DAC (Mod GRF 1-29) with peptides engaging the same primary receptor produces competition rather than synergy.
Central nervous system access
CJC-1295 without DAC (Mod GRF 1-29) reaches the central nervous system through one or more of three documented routes: direct blood-brain barrier transport, vagal-afferent signalling via the gut-brain axis, and direct action on cerebral vasculature in regions where the barrier is locally compromised. The compound's subq route(s) and ~30 min half-life set the timeline for CNS exposure. Same GHRH-receptor agonism as DAC variant. The CNS-relevant phenotype that emerges from this mechanism is the substrate of the cognitive effects described below.
Where CJC-1295 without DAC (Mod GRF 1-29) is used for serotonin modulation, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
For bdnf support, CJC-1295 without DAC (Mod GRF 1-29) is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.
Long-COVID Cognitive Recovery is one of the more-reported subjective benefits of CJC-1295 without DAC (Mod GRF 1-29) across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.
Where CJC-1295 without DAC (Mod GRF 1-29) is used for chronic neuroinflammation, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 100 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 60 mcg | 4–6 weeks initial cycle |
| Neuroprotection focus | SubQ | 100 mcg | 1-3x daily SubQ |
| Maintenance phase | SubQ | 70 mcg | Ongoing with periodic pauses |
Dose timing for CJC-1295 without DAC (Mod GRF 1-29) is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.
CJC-1295 without DAC (Mod GRF 1-29) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the cognitive neuroscience community.
- CJC-1295 without DAC (Mod GRF 1-29) + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in cognitive / neurological protocols.
- CJC-1295 without DAC (Mod GRF 1-29) + Selank: Modulates GABA-A receptor systems indirectly. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in cognitive / neurological protocols.
- CJC-1295 without DAC (Mod GRF 1-29) + Semax + Selank Blend: Semax raises BDNF and modulates dopamine systems; Selank stabilises GABAergic and serotonergic tone. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in cognitive / neurological protocols.
- CJC-1295 without DAC (Mod GRF 1-29) + DSIP: Mechanism remains incompletely characterised. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in cognitive / neurological protocols.
Short half-life produces fewer sustained-IGF-1 concerns than DAC variant. Site reactions common. Stack with ipamorelin for synergy.
Lens-specific safety considerations for cognitive / neurological use of CJC-1295 without DAC (Mod GRF 1-29): Short half-life produces fewer sustained-IGF-1 concerns than DAC variant. Site reactions common. Stack with ipamorelin for synergy. Additional cognitive / neurological monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| CJC-1295 without DAC (Mod GRF 1-29) | Short-acting GHRH analogue | ~30 min | Neuroprotection |
| Semax | ACTH-derived nootropic heptapeptide | CNS effect hours; plasma minutes | A Russian-developed analogue of ACTH(4-10) extended with a Pro-Gly-Pro tail for proteolytic stability — a clinically used nootropic and stroke recovery agent |
| Selank | Tuftsin-derived heptapeptide anxiolytic | CNS effect lasts hours; plasma short | A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder |
| DSIP | Neuropeptide (sleep) | ~7 min plasma; CNS effects longer | A short neuropeptide isolated from sleeping rabbits in 1977, of interest for its modulation of delta-wave sleep and stress resilience |
| Pinealon | Khavinson tripeptide (pineal-derived) | Short plasma; durable tissue effects | A Khavinson pineal-derived tripeptide of glutamate-aspartate-arginine, studied for neuroprotection and cognitive function in aged and ischemic models |
How long until I notice cognitive effects?
Does CJC-1295 without DAC (Mod GRF 1-29) cross the blood-brain barrier?
Is CJC-1295 without DAC (Mod GRF 1-29) appropriate alongside SSRIs or other psychiatric medications?
Can CJC-1295 without DAC (Mod GRF 1-29) be stacked with other nootropics?
Is CJC-1295 without DAC (Mod GRF 1-29) safe during pregnancy or breastfeeding?
What should I look for in CJC-1295 without DAC (Mod GRF 1-29) sourcing and quality?
Start a CJC-1295 without DAC (Mod GRF 1-29) Protocol
Alukard provides physician-supervised cognitive protocols with GMP-certified CJC-1295 without DAC (Mod GRF 1-29) and GMP-certified compounds and comprehensive neurological assessments.
Get ProtocolQuick Facts
- Molecular weight
- ~3367 Da
- Sequence length
- 29 aa
- Half-life
- ~30 min
- WADA
- Banned (S2 class)
- FDA
- Unapproved
- Research
- Mechanistic studies; off-label use widespread
Stack Partners
All cognitive / neurological applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for CJC-1295 without DAC (Mod GRF 1-29) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Cognitive / Neurological Protocol for CJC-1295 without DAC (Mod GRF 1-29)
Alukard provides physician-supervised cognitive protocols with GMP-certified compounds and comprehensive neurological assessments.
HIPAA Compliant · GMP Certified · Physician Supervised